Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non small Cell Lung Carcinoma who have EGFR-positive Tumors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms RADIANT
- Sponsors OSI Pharmaceuticals
- 02 Jun 2015 Final follow-up results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 22 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Jun 2014 Subgroup analysis of patients with epidermal growth factor receptor mutation-positive disease presented at the 50th Annual Meeting of the American Society of Clinical Oncology.